Stereotactic Radiosurgery in Patients With Head and Neck Region Tumours

The goal of this study is to evaluate the safety and efficacy of the stereotactic boost applied in patients with H\&N tumours.

Trial Details

NCT ID
NCT06472570
Phase
NA
Sponsor
Maria Sklodowska-Curie National Research Institute of Oncology
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Stereotactic radiotherapy boost
Locations (sample)
  • Gliwice, Gliwicw, Poland|50.29761,18.67658

Key Eligibility Criteria

  • Patients with squamous cell carcinoma (SCC) or adenoid cystic carcinoma (ACC) of the H\&N region qualified for radical treatment with (definitive o…
  • Patients with other malignant tumours of the H\&N region (sarcomas, neuroendocrine carcinomas, differentiated carcinomas, undifferentiated carcinom…
  • Patients with nonmalignant tumours of the H\&N region (tumour mixtus or paraganglioma) demanding definitive or adjuvant radiotherapy.
  • Age: 18-80 years. Biomedicines 2022, 10, 1484 5 of 12

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →